Roles
- Professor of Clinical Medicine
-
Biography
Gabriel N. Contreras, M.D., MPH, earned his medical degree in 1984 from the Autonomous University of Guadalajara in Mexico. He trained in Internal medicine, nephrology and hypertension, critical care medicine, and earned a degree of Master in Public Health between 1988 and 2003. In 1996, he joined the Miller School of Medicine at the University of Miami. During his time as faculty in the Department of Medicine, he has been involved in the development and establishment of a successful clinical research program in the Division of Nephrology & Hypertension with the accrual of 36 research grants, 116 publications in peer-reviewed journals, and 6 chapters published in textbooks. In the 29 years of his academic career, he has maintained research funding from different sources such as the National Institute of Health (NIH) and the pharmaceutical Industry. He has an ongoing commitment to improving kidney disease outcomes among racial and ethnic minorities at the Miller School of Medicine, University of Miami. He has particular interest in kidney involvement of systemic lupus erythematosus, a disease commonly named lupus nephritis, that particularly affects young women. He is a recognized expert nationally and internationally in the care of patients with lupus nephritis. He also is an expert in the care of critically ill patients with acute kidney injury. -
Education & Training
Education
Post Graduate Training
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 5 clinical trials.
-
This is a research study for subjects with active lupus nephritis.The purpose of this study is to find out if study treatment with MMF, prednisone and VIB4920 together is safe and more effective than study treatment with MMF and prednisone for lupus nephritis.The study will require up to 16clinic visits.
- Principal Investigator: Gabriel Contreras
- Study Phase: TBD
- Enrollment Status: Open
-
This is a multicenter study with an open-label design testing one dose of the investigational compound R3R01.The overall objective is to investigate the safety, tolerability, efficacy and pharmacokinetics of R3R01 administered daily for 3 months in AS patients with uncontrolled proteinuria on a maximum tolerated dose of ACEi or ARB therapy, and in FSGS patients with primary steroid-resistant FSGS.
- Principal Investigator: Gabriel Contreras
- Study Phase: Phase II
- Enrollment Status: Closed
-
A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy
- Principal Investigator: Gabriel Contreras
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
- Principal Investigator: Gabriel Contreras
- Study Phase: Phase 3
- Enrollment Status: Closed
-
1) To asses the predictors of both remission and relapse events in patients with lupus nephritis in South Florida.2) To asses the associations among remission and relapse events with kidney and patient survival. The first objective will be accomplished by comparing the baseline clinical characteristics of patients who achieved remission or relapse to those without those events. In addition, we will also estimate the hazard ratios of the baseline characteristics associated with remission or relapse. The second objective will be accomplished by estimating the hazard ratios associated with remission or relapse and kidney or patient survival. This information may be utilized to improve the future care of patients with lupus nephritis.Are age, ethnicity, gender, histologic class of lupus nephritis, blood pressure, serum creatinine, proteinuria, urinalysis sediment, ANA, antids DNA, complement C3 and C4, anticardiolipins, hematocrit and treatment associated with achieving remission of the nephritis?Are age, ethnicity, gender, histologic class of lupus nephritis, blood pressure, serum creatinine, proteinuria, urinalysis sediment, ANA, antids DNA, complement C3 and C4, anticardiolipins, hematocrit, treatment, and partial compared to complete remission associated with relapse of the nephritis?Do patients achieving remission have a lower risk for chronic kidney failure or death? Do the patients with relapse have a higher risk for chronic kidney failure or death?
- Principal Investigator: Gabriel Contreras
- Study Phase: N/A
- Enrollment Status: Open